Given that over 95% of soluble CD40 ligand (sCD40L) originates from platelets, it has been assumed that the level of sCD40L reflects platelet activation.[1] Consequently, it is important to consider that the predictive ability of sCD40L in acute coronary syndrome (ACS) may be diminished by antiplatelet medications, as these drugs inhibit platelet aggregation and the release of sCD40L. The gene discussed is CD40LG; the disease is acute coronary syndrome.